Cargando…
Combination Chemotherapy for Influenza
The emergence of pandemic H1N1 influenza viruses in April 2009 and the continuous evolution of highly pathogenic H5N1 influenza viruses underscore the urgency of novel approaches to chemotherapy for human influenza infection. Anti-influenza drugs are currently limited to the neuraminidase inhibitors...
Autores principales: | Govorkova, Elena A., Webster, Robert G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185732/ https://www.ncbi.nlm.nih.gov/pubmed/21994692 http://dx.doi.org/10.3390/v2081510 |
Ejemplares similares
-
What Is the Optimal Therapy for Patients with H5N1 Influenza?
por: White, Nicholas J., et al.
Publicado: (2009) -
Determination of Neuraminidase Kinetic Constants Using Whole Influenza Virus Preparations and Correction for Spectroscopic Interference by a Fluorogenic Substrate
por: Marathe, Bindumadhav M., et al.
Publicado: (2013) -
Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice
por: Marathe, Bindumadhav M., et al.
Publicado: (2016) -
Human-Like Receptor Specificity Does Not Affect the Neuraminidase-Inhibitor Susceptibility of H5N1 Influenza Viruses
por: Ilyushina, Natalia A., et al.
Publicado: (2008) -
Effect of Neuraminidase Inhibitor–Resistant Mutations on Pathogenicity of Clade 2.2 A/Turkey/15/06 (H5N1) Influenza Virus in Ferrets
por: Ilyushina, Natalia A., et al.
Publicado: (2010)